## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 2007P–0295]**

### Determination That INDERAL (Propranolol Hydrochloride) Tablets, 10 Milligrams, 20 Milligrams, and 90 Milligrams Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) has determined that INDERAL (propranolol hydrochloride (HCl)) Tablets, 10 milligrams (mg), 20 mg, and 90 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to the drug products, and it will allow FDA to approve ANDAs for propranolol HCl tablets, 10 mg, 20 mg, and 90 mg as long as they meet relevant legal and regulatory requirements.

**FOR FURTHER INFORMATION CONTACT:** Mary Catchings, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

**SUPPLEMENTARY INFORMATION:** In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98–417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the ''listed drug,'' which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug.

The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ''Approved Drug Products With Therapeutic Equivalence Evaluations,'' which is generally known as the ''Orange Book.'' Under FDA regulations, drugs are removed from the list if the agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

Under § 314.161(a) (21 CFR 314.161(a)), the agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved or (2) whenever a listed drug is voluntarily withdrawn from sale, and ANDAs that referred to the listed drug have been approved. Section 314.161(d) provides that if FDA determines that the listed drug was removed from sale for safety or effectiveness reasons, the agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug. FDA may not approve an ANDA that does not refer to a listed drug.

INDERAL (propranolol HCl) Tablets, 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 90 mg, are the subject of approved NDA 16–418 held by Wyeth Pharmaceuticals, Inc. (Wyeth). INDERAL is indicated in the treatment of hypertension, angina pectoris, atrial fibrillation, myocardial infarction, migraine headaches, essential tremors, hypertrophic subaortic stenosis, and pheochromocytoma. In tablet form, INDERAL is currently available in 40-, 60-, and 80-mg strengths. Wyeth discontinued marketing the tablet form in the 10-, 20-, and 90-mg strengths, and those products were moved from the prescription drug product list to the ''Discontinued Drug Product List'' section of the Orange Book.

In a citizen petition dated July 20, 2007 (Docket No. 2007P–0295/CP1), submitted under 21 CFR 10.25(a) and 10.30, Regulus Pharmaceutical Consulting, Inc., requested that the agency determine, as described in § 314.161, whether INDERAL (propranolol HCl) Tablets, 10 mg and 20 mg, were withdrawn from sale for reasons of safety or effectiveness. The petitioner has identified no data or other information suggesting that INDERAL Tablets, 10 mg and 20 mg, were withdrawn from sale as a result of safety or effectiveness concerns. Although the citizen petition did not address the 90-mg strength, FDA must make a determination regarding whether that strength was withdrawn for safety or efficacy reasons because generic versions of that strength are currently being marketed.

We have reviewed our records and determined that INDERAL Tablets, 10 mg, 20 mg, and 90 mg, were not withdrawn from sale for reasons of safety or effectiveness. We have also independently evaluated relevant literature and data for possible postmarketing adverse events and have found no information that would indicate that INDERAL Tablets, 10 mg, 20 mg, and 90 mg, were withdrawn from sale for reasons of safety or effectiveness.

After considering the citizen petition and reviewing its records, FDA has determined that, for the reasons outlined in this notice, INDERAL (propranolol HCl) Tablets, 10 mg, 20 mg, and 90 mg, were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the agency will continue to list INDERAL (propranolol HCl) Tablets, 10 mg, 20 mg, and 90 mg, in the ''Discontinued Drug Product List'' section of the Orange Book. The ''Discontinued Drug Product List'' delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDAs that refer to INDERAL (propranolol HCl) Tablets, 10 mg, 20 mg, and 90-mg, may be approved by the agency as long as they comply with relevant legal and regulatory requirements. If FDA determines that labeling for this drug product should be revised to meet current standards, the agency will advise ANDA applicants to submit such labeling.

Dated: January 2, 2008.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. E8–190 Filed 1–8–08; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[FDA No. 225–07–8004]**

### Memorandum of Understanding Between the Food and Drug Administration and Regents of the University of California

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and

the University of California, Davis campus (UC Davis). The purpose of this MOU is to establish terms of collaboration between FDA and UC Davis, focused primarily but not exclusively, in the areas of the safety and security of foods and cosmetics, animal feeds and veterinary products. Beyond the collaborations in the traditional academic programs for training, research and outreach, this MOU will also include UC Davis extended partnerships such as the Western Institute for Food Safety and Security, and the Center for Produce Safety.

**DATES:** The agreement became effective December 7, 2007.

**FOR FURTHER INFORMATION CONTACT:** Mary I. Poos, Officeof the Commissioner, Office of the Chief Medical Officer (HF–40), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–2825.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the **Federal Register**, the agency is publishing notice of this MOU.

Dated: December 26, 2007.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

**BILLING CODE 4160–01–S**

FDA Record No. 225-07-8004

MEMORANDUM OF UNDERSTANDING
between
THE UNITED STATES FOOD AND DRUG ADMINISTRATION
and the
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

## I. PURPOSE

The United States Food and Drug Administration (FDA) and The Regents of the University of California, on behalf of the University of California, Davis campus (UCD) (the Parties) have a shared interest in scientific progress in the diverse disciplines that directly and indirectly affect human and animal health. The Parties also endorse scientific training for faculty, students and staff to foster a well-grounded foundation in interdisciplinary fields in which academia and government share mutual interests.

This Memorandum of Understanding (MOU) establishes terms of collaboration between FDA and UCD to support these shared interests that can be pursued through a variety of programs including collaborative research, public outreach, extension activities, training, and exchange of scientists and staff, including sabbaticals, postdoctoral fellowships, and student internships.

## II. BACKGROUND

FDA is authorized to implement the Federal Food, Drug, and Cosmetic Act (the Act) as amended (21 U.S.C. 301). In fulfilling its responsibilities under the Act, FDA among other things, directs its activities toward protecting and promoting the public health by ensuring the safety and security of foods and cosmetics and of animal feeds and veterinary products (Appendix A). To accomplish its mission, FDA must stay abreast of the latest developments in research and also communicate with stakeholders about complex scientific and public health issues. Increased development of research, education, and outreach partnerships with UCD will greatly contribute to FDA's mission.

UCD is one of the nation's top public research universities and is part of one of the world's pre-eminent public university systems. Through a distinctive tradition of core-discipline excellence, interdisciplinary collaborations and productive partnerships, UCD teaches students to think critically, objectively and creatively and to be lifelong learners, engaged leaders and productive citizens; pursues research to advance knowledge and to address state, national and global challenges; and serves the public through the generation, broad dissemination and application of knowledge. Beyond the traditional academic programs, UCD is home to extended partnerships such the Western Institute for Food Safety and Security and the Center for Produce Safety that conduct research, training, and outreach focused on issues such as produce safety and security. The scientific, public health and policy expertise within FDA provide opportunities for collaborations that support the UCD mission and strategic themes to provide access to

**FDA Record No. 225-07-8004**

high-quality education, research discovery, and knowledge-based services responsive to both the promises and demands of the state and the nation in the new century.

III. SUBSTANCE OF THE AGREEMENT

This MOU forms the basis for development of scientific collaborations, outreach, and educational initiatives and intellectual partnerships between FDA and UCD. The types of activities expected to develop from this MOU include:

- Exchanges between university faculty and staff and FDA scientists and staff;
- Educational opportunities for qualified students (graduate and undergraduate), staff members, and faculty members in the Parties' laboratories, classrooms and offices;
- Joint meetings for education and research;
- Research collaborations;
- Sharing of unique facilities and equipment for increased cost efficiencies for scientific endeavors.

Under this MOU, joint efforts will be undertaken to obtain grants and other extramural funds to support collaborative research and training as permitted under appropriate statutory authority. Before any specific collaboration is initiated or implemented, the parties shall identify priorities and topics of mutual interest, and develop separate, written agreements for collaboration and sharing of resources. The terms and conditions of any such agreements will be in accordance with the applicable federal law and regulations and shall be negotiated and executed by appropriate representatives of institutions within UCD and FDA. Where applicable, these agreements shall incorporate by reference this MOU.

A. FDA agrees to:

For programs agreed to in writing, and in advance by both parties, FDA may, as permitted by applicable statutes and regulations and subject to the availability of funds, and as it deems appropriate, offer UCD the following:

- Laboratory and/or office space in support of activities under this agreement.
- Access to facilities and equipment, including necessary training and guidance, in so far as such use does not interfere with the primary mission of either party.
- Active participation in establishing collaborative research, education, extension and outreach efforts with faculty, students, and staff within UCD institutions.
- Continuing and frequent communication with faculty and staff.
- Openness and welcome to faculty, staff, and students wishing to visit FDA laboratories.
- Promulgation and communication of identified collaborative efforts through appropriate means.

B. University of California, Davis agrees to:

For programs agreed to in advance by both parties, UCD may offer FDA the following:

- Laboratory and/or office space in support of activities under this agreement.
- Access to facilities and equipment, including necessary training and guidance, in so far as such use does not interfere with the primary mission of either party.
- Active participation in establishing collaborative research, education, extension and outreach efforts with FDA scientists and staff.
- Continuing and frequent communication with FDA scientists and staff.
- Openness and welcome to FDA scientists and staff wishing to visit relevant UCD programs and laboratories.
- Promulgation and communication of identified collaborative efforts through appropriate means.

C. Additionally it is agreed that:

1. Rights to any inventions resulting from collaborative research will be solely-owned by the party if invented solely, or jointly-owned if invented jointly by the parties.

2. Institutions within UCD and FDA may decide to enter into Cooperative Research and Development Agreements (CRADA) specific to particular collaborative projects. The terms of such CRADAs will address Intellectual Property rights.

3. Proprietary and/or nonpublic information may not be disclosed under this MOU, unless such disclsoure is governed by appropriate confidentiality disclosure agreements, and unless such disclosure is permitted by law.

4. Each party shall comply with the other party's security procedures and policies regarding access to and use of facilities. Either party may restrict or limit access to its property and facilities, at any time, for any reason. UCD individuals participating in activities under this MOU on FDA property will comply with all applicable federal statutes and regulations.

5. It is recognized that from time to time FDA and entities within UCD will be sharing in expenses and may require compensation of either party by the other. As research projects are developed, details of how costs are to be shared will be agreed to in advance under other contractual mechanisms as appropriate and in compliance with all applicable federal requirements.

6. To the extent that Federal employees are involved in the implementation of specific projects, federal employee participation will be governed by all applicable statutes, regulations and policies on interactions with outside organizations, and reviewed for permissibility by the appropriate authority within the employee's agency on a case-by-case basis.

7. This agreement may be amended any time upon mutual agreement between the parties in writing.

IV. FINANCES AND RESOURCES

The foregoing represents the broad outline of the Parties' present intent to enter into specific agreements for collaborative efforts in intellectual areas of mutual interest to FDA and the entities within UCD. It does not create binding, enforceable obligations against any Party. All activities undertaken pursuant to the MOU are subject to the availability of personnel, resources, and funds. This MOU does not affect or supersede any existing or future agreements or arrangements among the Parties and does not affect the ability of the Parties to enter into other agreements or arrangements related to this MOU.

V. CONTACTS

The individuals to whom inquiries to FDA should be addressed are:

Mary I. Poos, Ph.D.
Director of Academic and Intellectual Partnerships
Office of the Commissioner
Food and Drug Administration
PKLN 13B-17, HF-10
5600 Fishers Lane
Rockville MD 20857
301-827-2825
Mary.Poos@fda.hhs.gov

Elizabeth Calvey, Ph.D.
Team Leader, Liaison and Partnership Team
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway (HFS-006)
College Park, MD 20740
301-436-1981
Elizabeth.Calvey@fda.hhs.gov

Marlene Wekell, Ph.D.
Director, Office of Research
Center for Veterinary Medicine
Food and Drug Administration
8401 Muirkirk Road (HFV-500)
Laurel, MD 20708
301-210-4136
Marlene.Wekell@fda.hhs.gov

FDA Record No. 225-07-8004

Mark Roh
Deputy Regional Director
Office of Regulatory Affairs
Food and Drug Administration
1301 Clay Street (HFR-PA1)
Oakland, CA 94612
510-637-3960
Mark.Roh@fda.hhs.gov

The individual to whom all inquires to UCD should be addressed is:

Ahmad Hakim-Elahi, Ph.D., J.D.
Director of Sponsored Programs
Office of Research
University of California, Davis
1850 Research Park Drive, Suite 300
Davis, CA 95618
(530) 747-3825

## VI. PERIOD OF AGREEEMENT

This MOU becomes effective upon signing by both parties and will continue in effect for five (5) years and may be renewed upon mutual agreement of the Parties.

## VII. REGULATIONS

This MOU and all associated agreements will be subject to the applicable policies, rules, regulations, and statutes under which FDA, UCD and the entities within UCD operate.

AGREED TO:

UNIVERSITY OF CALIFORNIA, DAVIS

BY: _____ October 16, 2007
Signature of authorized representative Date

Lynne U. Chronister
Associate Vice Chancellor for Research

UNITED STATES FOOD AND DRUG ADMINISTRATION

BY: _____ 12/7/07
Signature of authorized representative Date

Janet Woodcock, M.D.
Deputy Commissioner and Chief Medical Officer

FDA Record No. 225-07-8004

APPENDIX A

FDA Centers/Offices

The U.S. Food and Drug Administration (FDA) is comprised of product-oriented centers (Center for Food Safety and Applied Nutrition, Center for Veterinary Medicine, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health), a nationwide field force (Office of Regulatory Affairs), a cross-cutting research center (National Center for Toxicology Research), and the Office of the Commissioner. FDA is a scientific regulatory agency responsible for the safety of the nation's domestically produced and imported foods, cosmetics, animal feeds, veterinary products, drugs, biologics, medical devices, and radiological products. It is one of the oldest federal agencies whose primary function is consumer protection. The agency touches and directly influences the lives of everyone in the United States. FDA is recognized internationally as the leading food and drug regulatory agency in the world. Many foreign nations seek and receive FDA's help in improving and monitoring the safety of their products. FDA is part of the Executive Branch of the United States Government within the Department of Health and Human Services (DHHS) and the Public Health Service (PHS).

Any FDA center may participate in this MOU as appropriate. However, it is expected that initial interactions will primarily be with:

Center for Food Safety and Applied Nutrition (CFSAN)-
CFSAN, in conjunction with the Agency's field staff, is responsible for promoting and protecting the public's health by ensuring that the nation's food supply is safe, secure, sanitary, wholesome, and properly labeled, and that cosmetic products are safe, secure, and properly labeled.

Center for Veterinary Medicine (CVM)-
CVM is a consumer protection organization that fosters public and animal health by approving safe and effective products for animals and by enforcing applicable provisions of the Federal Food, Drug, and Cosmetic Act and other authorities.

Office of Regulatory Affairs (ORA)-
ORA is the lead office for all Field activities of the Food and Drug Administration including inspection of food, feed, and medical product manufacturing, transport and storage facilities for compliance with exiting law; as well as enforcement activities. It includes the Office of Criminal Investigations

**FDA Record No. 225-07-8004**

APPENDIX B

University of California, Davis

UCD is one of the nation's top public research universities. Through a distinctive tradition of core-discipline excellence, interdisciplinary collaborations and productive partnerships, UCD teaches students to think critically, creatively and to be lifelong learners, engaged leaders and productive citizens; pursues research to advance knowledge and to address state, national and global challenges; and serves the public through the generation, dissemination and application of knowledge. The primary core of UCD is comprised of the College of Agricultural and Environmental Sciences, College of Biological Sciences, College of Engineering, and College of Letters and Sciences, along with five professional schools, School of Veterinary Medicine, School of Medicine, School of Law, School of Education, and the Graduate School of Management. Complimenting this consortium of Colleges and Professional Schools is a long list of mission-specific Institutes and Centers that enhance the teaching, research, outreach, and service that is conducted by UCD. These Institutes and Centers, such as the Western Institute of Food Safety and Security, allow UCD to quickly and effectively address a wide range of societal concerns and issues, such as emerging threats to our nation's food safety and security. Lastly, as a Land Grant University, UCD helps comprise the Division of Agriculture and Natural Resources which is a statewide network of University of California researchers and educators dedicated to the creation, development and application of knowledge in agricultural, natural and human resources.

Any College, Professional School, Center, Institute, or other such organized research unit may participate in this MOU as appropriate. We anticipate that initial interaction will quickly occur with academic entities that are engaged in conducting research, education, outreach, and service in area of food safety and security anywhere along the farm-to-fork continuum for either plant- or animal-foods of origin. For example:

Western Institute of Food Safety and Security

Specific Departments within the School of Veterinary Medicine (Population Health and Reproduction; Medicine and Epidemiology)

Specific Departments within the College of Agricultural and Environmental Sciences (Nutrition; Plant Sciences; Land, Air, and Water Resources; Food Science and Technology)

Specific Departments within the College of Engineering (Biological and Agricultural Engineering)

Specialists of the Division of Agriculture and Natural Resources

A sampling of specific centers, institutes, organized research units, central facilities and resources at the University of California, Davis that may participate in this MOU follows:

FDA Record No. 225-07-8004

College of Agricultural and Environmental Sciences Agricultural Experiment Station
- Agricultural & Environmental Informatics Facility
- Agricultural Sustainability Institute
- California Crop Improvement Association
- California Institute of Food and Agricultural Research
- Center for Vector-Borne Disease Research
- Foundation Plant Services
- Foundation Seed Service
- Genomics Facility
- Greenhouses
- Long -Term Research on Agricultural Systems
- Robert Mondavi Institute for Wine and Food Science
- Seed Biotechnology Center
- Research and Information Centers
  - Center for Agronomic Crops
  - Center for Consumer Research
  - Dairy Research and Information Center
  - Fruit & Nut Research and Information Center
  - Ornamental Horticulture Research and Information Center
  - Postharvest Technology Research and Information Center
  - Seed Biotechnology Center
  - Weed Research and Information Center
  - Vegetable Research and Information Center

School of Veterinary Medicine
- California Animal Health & Food Safety Laboratory System
- Center for Food Animal Health
- Center for Laboratory Animal Science
- Center for VectorBorne Diseases
- Comparative Pathology Laboratory
- Dairy Food Safety Laboratory
- International Laboratory of Molecular Biology for Tropical Diseases
- Veterinary Genetics Laboratory
- Western Institute for Food Safety and Security

Central Facilities
- Controlled Environment Facility
- Crocker Nuclear Laboratory
- McClellan Nuclear Radiation Center
- Molecular Structure Facility
- Nuclear Magnetic Resonance Facility

Interdisciplinary Research & Teaching Programs
- Agricultural Health and Safety Center
- Agricultural Issues Center

**FDA Record No. 225-07-8004**

Biotechnology Program
California Institute of Food and Agricultural Research
CalSpace: Center of Excellence Agriculture, Natural Resources, Environment
Center for Animal Welfare
Center for Ecological Health Research
Center for Environmental Health Sciences
Center for Health and the Environment
Dairy Research and Information Center
Genome Center
Nanomaterials in the Environment, Agriculture and Technology
Partnership for Plant Genomics Education
Small Farm Center
Statewide Integrated Pest Management Program
Sustainable Agriculture Farming Systems Project
Sustainable Agricultural Research and Education Program
Toxic Substances Research and Teaching Program
UC Groundwater Cooperative Extension Program
UC Biotechnology Research and Education Program
UC Statewide Integrated Pest Management Program
UC Toxic Substances Research and Teaching Program
Western Center for Agricultural Health and Safety

[FR Doc. 08–30 Filed 1–8–08; 8:45 am]
**BILLING CODE 4160–01–C**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; Patient Oriented and Career Enhancement Awards for Stem Cell Research.

*Date:* February 20–21, 2008.

*Time:* 8 a.m. to 1 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard Marriott, 2899 Jefferson Davis Highway, Arlington, VA 22202.

*Contact Person:* Mark Roltsch, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7192, Bethesda, MD 20892–7924, 301–435–0287, *roltschm@nhlbi.nih.gov.*

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; Pathobiology Program Project.

*Date:* February 21, 2008.

*Time:* 10 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Four Point Sheraton BWI, 7032 Elm Road, Baltimore, MD 21240.

*Contact Person:* Charles Joyce, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7196, Bethesda, MD 20892–7924, 301–435–0288, *cjoyce@nhlbi.nih.gov.*

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; Coagulation Program Project.

*Date:* February 22, 2008.

*Time:* 10 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Four Point Sheraton BWI, 7032 Elm Road, Baltimore, MD 21240.

*Contact Person:* Charles Joyce, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7196, Bethesda, MD 20892–7924, 301–435–0288, *cjoyce@nhlbi.nih.gov.*

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; Resource Related Research Project.

*Date:* February 28, 2008.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Keary A Cope, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7190, Bethesda, MD 20892–7924, 301–435–2222, *copeka@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 3, 2008.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 08–41 Filed 1–8–08; 8:45 am]
**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice